Download PDF
Z Geburtshilfe Neonatol 2017; 221(06): 265-271
DOI: 10.1055/s-0043-116016
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Sinnvolle Steroidprophylaxe bei drohender Frühgeburt – State of the art

Antenatal Steroid Therapy in Threatened Premature Birth – State of the Art
Dimitra Stavropoulou
1   Neonatologie und pädiatrische Intensivmedizin, Universitätsklinikum Freiburg, Freiburg
,
Roland Hentschel
1   Neonatologie und pädiatrische Intensivmedizin, Universitätsklinikum Freiburg, Freiburg
› Author Affiliations
Further Information

Publication History

eingereicht 12 March 2017

akzeptiert   20 June 2017

Publication Date:
15 September 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die vorliegende Arbeit versucht, anhand der aktuellen Literatur eine Übersicht über die zurzeit geltenden Empfehlungen zur sinnvollen Lungenreife-Induktionstherapie zu geben. Fokussiert wird insbesondere auf spezielle Situationen, wie die Chorioamnionitis, die intrauterine Wachstumsretardierung und die Präeklampsie, die gehäuft zu einer Frühgeburt führen. Zusätzlich werden Aspekte der antenatalen Steroidtherapie erläutert, die trotz der weit verbreiteten Anwendung noch einer Klärung bedürfen. Darunter fällt insbesondere die repetitive Gabe der Steroidtherapie. Anhand der Cochrane Analyse vom 2015 werden Vor- und Nachteile für die Kinder und die Schwangeren erläutert. Ungenügend sind weiterhin die Daten über die Anwendung der antenatalen Steroidtherapie bei Mehrlingsschwangerschaften.

Abstract

The aim of this work is to provide an overview of the recommendations in the current literature for the induction of lung maturation therapy. In particular, special attention is focused on specific situations, such as chorioamnionitis, intrauterine growth retardation and preeclampsia, which often lead to premature birth. Additionally, some aspects of antenatal steroid therapy, despite its widespread use, still require clarification. Among them is the repetitive administration of steroid therapy. On the basis of the Cochrane analysis of 2015, advantages and disadvantages for children and pregnant women are explained. Furthermore, the data on the use of antenatal steroid therapy in multiple pregnancies remain insufficient.

Schlüsselwörter

antenatale Steroide - Lungenreifung - Betamethason - Mortalität - Morbidität - Frühgeburt

Key words

antenatal care - lung maturation - Betamethasone - prematurity - mortality - morbidity
 

  • Literatur

  • 1 Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. Journal of Endocrinology 1969; 45: 515-523
    CrossrefPubMedGoogle Scholar
  • 2 Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-525
    CrossrefPubMedGoogle Scholar
  • 3 National Institutes of Health. Report on the consensus development conference on the effect of corticosteroids for fetal maturation on perinatal outcomes. U.S. Department of Health and Human Services, Public Health Service. 1994;
    PubMed
  • 4 Roberts D, Brown J, Medley N et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017
    PubMed
  • 5 Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gyneco 1995; 173: 322-335
    CrossrefPubMedGoogle Scholar
  • 6 Hentschel R. Die Lunge des Neugeborenen. Neonatologie Scan 2014; 03: 49-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Michael AE, Papageorghiou AT. Potential significance of physiological and pharmacological glucocorticoids in early pregnancy. Human reproduction update 2008; 14: 497-517
    CrossrefPubMedGoogle Scholar
  • 8 Muglia LJ, Bae DS, Brown TT. et al. Proliferation and differentiation defects during lung development in corticotropin-releasing hormone–deficient mice. American Journal of Respiratory Cell and Molecular Biology 1999; 20: 181-188
    CrossrefPubMedGoogle Scholar
  • 9 Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. American Journal of Physiology-Lung Cellular and Molecular Physiology 2006; L209-L221
    PubMedGoogle Scholar
  • 10 Lefebvre Y, Marier R, Amyot G. et al. Maternal, fetal, and intra-amniotic hormonal and biologic changes resulting from a single dose of hydrocortisone injected in the intra-amniotic compartment. American journal of obstetrics and gynecology 1976; 125: 609-612
    CrossrefPubMedGoogle Scholar
  • 11 Murphy BEP. The absorption by the human fetus of intra-amniotically injected cortisol. Journal of steroid biochemistry 1982; 16: 415-417
    CrossrefPubMedGoogle Scholar
  • 12 Petersen MC, Collier CB, Ashley JJ. et al. Disposition of betamethasone in parturient women after intravenous administration. European journal of clinical pharmacology 1983; 25: 803-810
    CrossrefPubMedGoogle Scholar
  • 13 Egerman RS, Mercer BM, Doss JL. et al. A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. Am J Obstet Gyneco 1998; 179: 1120-1123
    CrossrefPubMedGoogle Scholar
  • 14 Slotkin TA, Zhang J, McCook EC. et al. Glucocorticoid administration alters nuclear transcription factors in fetal rat brain: implications for the use of antenatal steroids. Developmental brain research 1998; 111: 11-24
    CrossrefPubMedGoogle Scholar
  • 15 Velayo C, Ito T, Chisaka H. et al. Effects of antenatal steroid therapy on neurodevelopment in an IUGR mouse model. Fetal diagnosis and therapy 2010; 28: 79-86
    CrossrefPubMedGoogle Scholar
  • 16 Remesel A, San Feliciano L, Isidoro-García M. et al. Effects of antenatal betamethasone and dexamethasone on the lung expression of vascular endothelial growth factor and alveolarization in newborn rats exposed to acute hypoxia and recovered in normoxia or hyperoxia. Neonatology 2010; 98: 313-320
    CrossrefPubMedGoogle Scholar
  • 17 San Feliciano L, Remesal A, Isidoro-García M. et al. Dexamethasone and betamethasone for prenatal lung maturation: differences in vascular endothelial growth factor expression and alveolarization in rats. Neonatology 2011; 100: 105-110
    CrossrefPubMedGoogle Scholar
  • 18 Baud O, Foix-L'Helias L, Kaminski M. et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. New England Journal of Medicine 1999; 341: 1190-1196
    CrossrefPubMedGoogle Scholar
  • 19 Lee BH, Stoll BJ, McDonald SA. et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006; 117: 1503-1510
    CrossrefPubMedGoogle Scholar
  • 20 Elimian A. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstetrics & Gynecology 2007; 110: 931
    CrossrefPubMedGoogle Scholar
  • 21 Brownfoot FC, Gagliardi DI, Bain E et al. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. The Cochrane Library 2013
    PubMed
  • 22 Hanke K, Hartz A, Manz M. et al. Preterm prelabor rupture of membranes and outcome of very-low-birth-weight infants in the German Neonatal Network. PloS one 2005; 10: e0122564
    PubMedGoogle Scholar
  • 23 Foix-L’Helias L, Baud O, Lenclen R. et al. Benefit of antenatal glucocorticoids according to the cause of very premature birth. Archives of Disease in Childhood-Fetal and Neonatal Edition 2005; 90: F46-F48
    CrossrefPubMedGoogle Scholar
  • 24 Gyamfi C, Mele L, Wapner RJ. et al. The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. American journal of obstetrics and gynecology 2010; 203: 219-e1
    PubMedGoogle Scholar
  • 25 Ment LR, Oh W, Ehrenkranz RA. et al. Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. American journal of obstetrics and gynecology 1995; 172: 795-800
    CrossrefPubMedGoogle Scholar
  • 26 Moïse AA, Wearden ME, Kozinetz CA. et al. Antenatal steroids are associated with less need for blood pressure support in extremely premature infants. Pediatrics 1995; 95: 845-850
    CrossrefPubMedGoogle Scholar
  • 27 August D, Kandasamy Y. Significance of antenatal glucocorticoid exposure for pressure injury prevalence in neonates. Journal of neonatal-perinatal medicine 2016; 9: 23-29
    PubMedGoogle Scholar
  • 28 Sweet DG, Carnielli V, Greisen G. et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update. Neonatology 2013; 103: 353-368
    CrossrefPubMedGoogle Scholar
  • 29 Empfehlungen zum Vorgehen beim vorzeitigen Blasensprung. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). 2006; AWMF-Leitlinien-Register, Nr. 015/029
    PubMed
  • 30 Roberts D. Antenatal corticosteroids to reduce neonatal morbidity and mortality. Royal College of Obstetricians and Gynaecologists; 2010. Green Top guideline
    Google Scholar
  • 31 Althabe F, Belizán JM, McClure EM. et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. The Lancet 2015; 385: 629-639
    CrossrefPubMedGoogle Scholar
  • 32 Althabe F, Thorsten V, Klein K. et al. The Antenatal Corticosteroids Trial (ACT)’s explanations for neonatal mortality-a secondary analysis. Reproductive health 2016; 13: 62
    CrossrefPubMedGoogle Scholar
  • 33 Garite TJ, Rumney PJ, Briggs GG. et al. A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24 to 28 week's gestation. American journal of obstetrics and gynecology 1992; 166: 646-651
    CrossrefPubMedGoogle Scholar
  • 34 Costeloe K. EPICure: facts and figures: why preterm labour should be treated. BJOG: An International Journal of Obstetrics & Gynaecology 2006; 113: 10-12
    PubMedGoogle Scholar
  • 35 Hayes EJ, Paul DA, Stahl GE. et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. Obstetrics & Gynecology 2008; 111: 921-926
    CrossrefPubMedGoogle Scholar
  • 36 Mori R, Kusuda S, Fujimura M. Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. The Journal of pediatrics 2011; 159: 110-114
    CrossrefPubMedGoogle Scholar
  • 37 Serenius F, Källén K, Blennow M. et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. Jama 2013; 309: 1810-1820
    CrossrefPubMedGoogle Scholar
  • 38 San Feliciano L, Remesal A, Isidoro-García M. et al. Dexamethasone and betamethasone for prenatal lung maturation: differences in vascular endothelial growth factor expression and alveolarization in rats. Neonatology 2011; 100: 105-110
    CrossrefPubMedGoogle Scholar
  • 39 Been JV, Degraeuwe PL, Kramer BW. etal. Antenatal steroids and neonatal outcome after chorioamnionitis: a meta – analysis. BJOG: An International Journal of Obstetrics & Gynaecology 2011; 118: 113-122
    CrossrefPubMedGoogle Scholar
  • 40 Miyazaki K, Furuhashi M, Ishikawa K. et al. The effects of antenatal corticosteroids therapy on very preterm infants after chorioamnionitis. Archives of gynecology and obstetrics 2014; 289: 1185-1190
    CrossrefPubMedGoogle Scholar
  • 41 Torrance HL, Derks JB, Scherjon SA. et al. Is antenatal steroid treatment effective in preterm IUGR fetuses?. Acta obstetricia et gynecologica Scandinavica 2009; 88: 1068-1073
    CrossrefPubMedGoogle Scholar
  • 42 Bernstein IM, Horbar JD, Badger GJ. et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. American journal of obstetrics and gynecology 2000; 182: 198-206
    CrossrefPubMedGoogle Scholar
  • 43 Blickstein I, Shinwell ES, Lusky A. et al. Plurality-dependent risk of respiratory distress syndrome among very-low-birth-weight infants and antepartum corticosteroid treatment. American journal of obstetrics and gynecology 2005; 192: 360-364
    CrossrefPubMedGoogle Scholar
  • 44 Blickstein I, Reichman B, Lusky A. et al. Plurality-dependent risk of severe intraventricular hemorrhage among very low birth weight infants and antepartum corticosteroid treatment. American journal of obstetrics and gynecolog 2006; 194: 1329-1333
    PubMedGoogle Scholar
  • 45 Murphy DJ, Caukwell S, Joels LA. et al. Cohort study of the neonatal outcome of twin pregnancies that were treated with prophylactic or rescue antenatal corticosteroids. American journal of obstetrics and gynecology 2002; 187: 483-488
    CrossrefPubMedGoogle Scholar
  • 46 Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. Bmj 2005; 331: 662
    CrossrefPubMedGoogle Scholar
  • 47 Walters DV, Olver RE. The role of catecholamines in lung liquid absorption at birth. Pediatr Res 1978; 12: 239-242
    CrossrefPubMedGoogle Scholar
  • 48 Madar J, Richmond S, Hey E. Surfactant-deficient respiratory distress after elective delivery at ‘term’. Acta Paediatrica 1999; 88: 1244-1248
    CrossrefPubMedGoogle Scholar
  • 49 Stutchfield PR, Whitaker R, Gliddon AE. et al. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Archives of Disease in Childhood-Fetal and Neonatal Edition 2013; 98: F195-F200
    CrossrefPubMedGoogle Scholar
  • 50 Vermillion ST, Soper DE, Newman RB. Is betamethasone effective longer than 7 days after treatment?. Obstetrics & Gynecology 2001; 97: 491-493
    PubMedGoogle Scholar
  • 51 Vidaeff AC, Ramin SM, Gilstrap LC. et al. Characterization of corticosteroid redosing in an in vitro cell line model. American journal of obstetrics and gynecology 2004; 191: 1403-1408
    CrossrefPubMedGoogle Scholar
  • 52 Crowther CA, McKinlay CJ, Middleton P et al. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. The Cochrane Library 2015
    PubMed